Skip to main content

Table 2 PSMA-ligand PET results and radiotherapy of metastases

From: Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy

PSMA-ligand PET results N (%)
Number of PSMA-ligand positive lesions 185 (100
Total number of LNs 128 (69.2)
 Iliac LNs 67 (36.2)
 Obturator LNs 6 (3.2)
 Perirectal LNs 4 (2.2)
 Periaortic/interaortocaval LNs 51 (27.6)
Total number of bone metastases 45 (24.3)
 Pelvic bone 24 (13.0)
 Spinal bone 10 (5.4)
 Other 11 (5.9)
Number of visceral metastases 12 (6.5)
Concurrent ADT at radiotherapy 13 (16.7)
Radiotherapy of metastases N (%)
Radiotherapy of LNs 128 (100)
CF-RT 95 (74.2)
SBRT 5 (3.9)
CF-RT plus SBRT 15 (11.7)
CF-RT with SIB 13 (10.2)
Median dose, EQD2/1.5 Gy (range) 50.9 (50.0–76.1)
  N (%)
Radiotherapy of bone metastases 45 (100%)
CF-RT 26 (57.8)
SBRT 15 (33.3)
CF-RT plus SBRT 0 (0)
CF-RT with SIB 4 (8.9)
Median dose, EQD2/1.5 Gy (range) 51.4 (46.4–108.8
  N (%)
Radiotherapy of visceral metastases 12 (100)
CF-RT 8 (66.7)
SBRT 4 (33.3)
CF-RT plus SBRT 0
CF-RT with SIB 0
Median dose, EQD2/1.5 Gy (range) 64.7 (57.8–85.0)
  1. ADT androgen deprivation therapy, CF-RT conventionally fractionated radiotherapy type, Gy Gray, LNs lymph node metastases, PCa prostate cancer, PSMA-PET prostate-specific membrane antigen positron emission tomography, PSA prostate-specific antigen, RP radical prostatectomy, sRT salvage radiotherapy, SBRT stereotactic body radiation therapy, SIB simultaneous integrated boost